Published in J Virol on June 13, 2012
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem (2013) 1.17
An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol (2012) 1.04
Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol (2013) 1.00
Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis (2013) 0.99
Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection. J Virol (2015) 0.85
Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers. PLoS Pathog (2016) 0.78
Flow Cytometry: Impact on Early Drug Discovery. J Biomol Screen (2015) 0.78
Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function. AIDS Res Hum Retroviruses (2015) 0.76
HIV-1 integration in the human genome favors active genes and local hotspots. Cell (2002) 12.60
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev (1997) 6.88
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J (2003) 6.11
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature (2001) 5.14
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev (1997) 5.13
Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J (1996) 5.10
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood (2010) 4.99
Strain Specificity and Production of Antibiotic Substances: VII. Production of Actinomycin by Different Actinomycetes. Proc Natl Acad Sci U S A (1946) 4.43
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc Natl Acad Sci U S A (1976) 3.70
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A (1998) 3.62
Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. J Biol Chem (1982) 3.48
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17
Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood (2008) 3.05
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe (2008) 2.81
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75
Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J (2007) 2.74
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A (1996) 2.72
Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol (2002) 2.64
Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J (2007) 2.37
HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog (2007) 2.33
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J (2007) 2.20
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One (2010) 2.09
Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe (2008) 2.08
Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol (2010) 2.01
Inactivation of the HIV LTR by DNA CpG methylation: evidence for a role in latency. EMBO J (1990) 1.98
Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis (2002) 1.91
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. EMBO J (2006) 1.68
Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses (2009) 1.66
Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog (2011) 1.64
Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol (2009) 1.55
Negative elongation factor NELF represses human immunodeficiency virus transcription by pausing the RNA polymerase II complex. J Biol Chem (2007) 1.51
Methylation as a modulator of expression of human immunodeficiency virus. J Virol (1987) 1.47
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood (1992) 1.46
NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem (2001) 1.39
Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol (2011) 1.34
Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J Infect Dis (2008) 1.32
The transcriptional inhibitors, actinomycin D and alpha-amanitin, activate the HIV-1 promoter and favor phosphorylation of the RNA polymerase II C-terminal domain. J Biol Chem (1999) 1.29
5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood (1984) 1.27
Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J Virol (2003) 1.15
Human T cell transcription factor GATA-3 stimulates HIV-1 expression. Nucleic Acids Res (1993) 1.10
Hexamethylene bisacetamide activates the human immunodeficiency virus type 1 provirus by an NF-kappa B-independent mechanism. J Gen Virol (1993) 1.03
Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS (2000) 1.03
New antitumor antibiotics aclacinomycins A and B. J Antibiot (Tokyo) (1975) 1.01
Integration site selection by lentiviruses: biology and possible control. Curr Top Microbiol Immunol (2002) 1.00
Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine. J Clin Invest (1984) 0.99
Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis. Exp Hematol (1982) 0.96
Valproic acid and HIV-1 latency: beyond the sound bite. Retrovirology (2005) 0.96
Solution structure of actinomycin-DNA complexes: drug intercalation at isolated G-C sites. J Biomol NMR (1991) 0.94
Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity. J Virol (2012) 0.94
The receptor tyrosine kinase RON represses HIV-1 transcription by targeting RNA polymerase II processivity. J Immunol (2008) 0.93
Optimization of HIV-1 infectivity assays. Biotechniques (2007) 0.91
High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds. Assay Drug Dev Technol (2007) 0.88
Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription. Antimicrob Agents Chemother (2004) 0.87
Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med (1992) 0.85
Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J Virol (2010) 0.85
Inhibition of glycoprotein biosynthesis by the inducers of HL-60 cell differentiation, aclacinomycin A and marcellomycin. Cancer Res (1984) 0.85
Structure-activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukemia cells by anthracyclines. Cancer Res (1982) 0.83
Cellular and clinical pharmacology of low-dose ara-C. Semin Oncol (1985) 0.81
Targeting HIV reservoirs with valproic acid. Hopkins HIV Rep (2005) 0.81
CD32A (Fc gamma RIIa) mRNA expression and regulation in blood monocytes and cell lines. Mol Immunol (1992) 0.80
Nuclear transcription factor GATA-1 is activated during aclacinomycin-induced erythroid differentiation. Biol Cell (2002) 0.80
Terminal differentiation of human erythroleukemia cell line K562 induced by aphidicolin. Exp Cell Res (1990) 0.80
Evaluation of some anthracycline antibiotics in an in vivo model for studying drug-induced human leukemia cell differentiation. Cancer Res (1983) 0.79
Essential role of c-myc in ara-C-induced differentiation of human erythroleukemia cells. Leukemia (1994) 0.79
Interaction of actinomycin with deoxyribonucleic acid. Nature (1960) 0.78
Hematopoietic transcription factor GATA-2 activates transcription from HIV-1 long terminal repeat. AIDS (1998) 0.78
Clinical studies of actinomycin D. Ann N Y Acad Sci (1960) 0.77
Effects of inducers of erythroid differentiation of human leukemia K562 cells on vincristine-resistant K562/VCR cells. Leuk Res (1983) 0.77
Induction of erythroid differentiation by the anthracycline antitumor antibiotics, aclacinomycin A, musettamycin and marcellomycin. Leuk Res (1986) 0.76
Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. An oncostatic anthracyclin that is rarely cardiotoxic and induces no alopecia. Cancer Chemother Pharmacol (1978) 0.76
Induction of differentiation in Friend-erythroleukemia cells by aclacinomycin A: early transient decrease in c-myc and c-myb mRNA levels. Leukemia (1992) 0.76
Cycloheximide protection against actinomycin D cytotoxicity. J Cell Physiol (1992) 0.75
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A (2004) 4.37
Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell (2006) 4.13
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell (2011) 3.49
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood (2007) 2.35
Relationships of Indoor, Outdoor, and Personal Air (RIOPA). Part I. Collection methods and descriptive analyses. Res Rep Health Eff Inst (2005) 1.95
Environmental tobacco smoke exposure and perinatal outcomes: a systematic review and meta-analyses. Acta Obstet Gynecol Scand (2010) 1.80
The growth rate of Mycobacterium smegmatis depends on sufficient porin-mediated influx of nutrients. Mol Microbiol (2005) 1.76
A synonymous single nucleotide polymorphism in DeltaF508 CFTR alters the secondary structure of the mRNA and the expression of the mutant protein. J Biol Chem (2010) 1.75
Barbershops as hypertension detection, referral, and follow-up centers for black men. Hypertension (2007) 1.74
The SaeR/S gene regulatory system is essential for innate immune evasion by Staphylococcus aureus. J Infect Dis (2009) 1.74
Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol (2009) 1.56
Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol (2009) 1.55
Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2013) 1.51
Polycyclic aromatic hydrocarbons in the indoor and outdoor air of three cities in the U.S. Environ Sci Technol (2002) 1.51
Neurologists warn about link between chiropractic, stroke. CMAJ (2002) 1.45
Tethering KSRP, a decay-promoting AU-rich element-binding protein, to mRNAs elicits mRNA decay. Mol Cell Biol (2006) 1.44
The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT Small Vessel trial. Catheter Cardiovasc Interv (2012) 1.44
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol (2008) 1.44
Influence of ambient (outdoor) sources on residential indoor and personal PM2.5 concentrations: analyses of RIOPA data. J Expo Anal Environ Epidemiol (2005) 1.42
Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci (2008) 1.38
Amiodarone rescue therapy for severe decompensated heart failure initially unsuitable for beta-blockers. J Cardiovasc Pharmacol Ther (2003) 1.38
Factors associated with hypertension awareness, treatment, and control in Dallas County, Texas. Arch Intern Med (2008) 1.35
Differences in "bottom-up" and "top-down" neural activity in current and former cigarette smokers: Evidence for neural substrates which may promote nicotine abstinence through increased cognitive control. Neuroimage (2011) 1.23
Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol (2014) 1.19
Rv1698 of Mycobacterium tuberculosis represents a new class of channel-forming outer membrane proteins. J Biol Chem (2008) 1.16
Consideration of multiple chronic diseases in randomized controlled trials. JAMA (2011) 1.15
High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J Virol (2013) 1.15
Identification of two Mycobacterium smegmatis lipoproteins exported by a SecA2-dependent pathway. J Bacteriol (2007) 1.13
Differentiation of the lateral compartment of the cochlea requires a temporally restricted FGF20 signal. PLoS Biol (2012) 1.10
Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells. Mol Cell Biol (2002) 1.10
Assessment of impairment and activity limitations in the critically ill: a systematic review of measurement instruments and their clinimetric properties. Intensive Care Med (2015) 1.08
The desire for hastened death in patients with metastatic cancer. J Pain Symptom Manage (2007) 1.07
T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. Biotechniques (2006) 1.06
Open trial of family-based treatment for full and partial anorexia nervosa in adolescence: evidence of successful dissemination. J Am Acad Child Adolesc Psychiatry (2007) 1.06
Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents. AIDS (2007) 1.05
Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids. Chem Biol (2011) 1.05
Suppressor of cytokine signaling 3 inhibits antiviral IFN-beta signaling to enhance HIV-1 replication in macrophages. J Immunol (2010) 1.05
An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol (2012) 1.04
Immediate replacement of fishing with dairying by the earliest farmers of the Northeast Atlantic archipelagos. Proc Biol Sci (2014) 1.01
Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin. Hum Mol Genet (2003) 1.01
Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol (2013) 1.00
Fine organic particulate matter dominates indoor-generated PM2.5 in RIOPA homes. J Expo Sci Environ Epidemiol (2006) 1.00
Copper-boosting compounds: a novel concept for antimycobacterial drug discovery. Antimicrob Agents Chemother (2012) 1.00
The contribution of attachment security and social support to depressive symptoms in patients with metastatic cancer. Psychooncology (2007) 0.98
Mycobacteria, metals, and the macrophage. Immunol Rev (2015) 0.97
Differences in Bcl-2 expression by T-cell subsets alter their balance after in vivo irradiation to favor CD4+Bcl-2hi NKT cells. Eur J Immunol (2009) 0.96
Ambulance diversion as a proxy for emergency department crowding: the effect on pediatric mortality in a metropolitan area. Acad Emerg Med (2008) 0.96
Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure. J Med Chem (2010) 0.95
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol (2010) 0.95
Prognostic significance of p27(kip-1) expression in colorectal adenocarcinomas is associated with tumor stage. Clin Cancer Res (2004) 0.94
Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity. J Virol (2012) 0.94
Qualitative meta-synthesis of survivors' work experiences and the development of strategies to facilitate return to work. J Cancer Surviv (2014) 0.94
Reed Elsevier and the arms trade revisited. Lancet (2007) 0.93
The silent codon change I507-ATC->ATT contributes to the severity of the ΔF508 CFTR channel dysfunction. FASEB J (2013) 0.93
Selective resistance of CD44hi T cells to p53-dependent cell death results in persistence of immunologic memory after total body irradiation. J Immunol (2011) 0.92
Validating a firefly luciferase-based high-throughput screening assay for antimalarial drug discovery. Assay Drug Dev Technol (2011) 0.92
Short-term Flt3L treatment effectively mobilizes functional macaque dendritic cells. J Leukoc Biol (2004) 0.92
Comparing administrative and survey data for ascertaining cases of irritable bowel syndrome: a population-based investigation. BMC Health Serv Res (2010) 0.91
Optimization of HIV-1 infectivity assays. Biotechniques (2007) 0.91
Adjusting transgene expression levels in lymphocytes with a set of inducible promoters. J Gene Med (2010) 0.90
Bull bars and vulnerable road users. Traffic Inj Prev (2012) 0.90
Ethnic Differences in Attributions and Treatment Expectancies for Adolescent Depression. Int J Cogn Ther (2008) 0.90
Host factor transcriptional regulation contributes to preferential expression of HIV type 1 in IL-4-producing CD4 T cells. J Immunol (2012) 0.88
Clinical and molecular characterization of S1118F-CFTR. Pediatr Pulmonol (2009) 0.88
High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds. Assay Drug Dev Technol (2007) 0.88
Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors. Virology (2011) 0.88
Aggregation behavior in water of new imidazolium and pyrrolidinium alkycarboxylates protic ionic liquids. J Colloid Interface Sci (2009) 0.87
Temperature dependence of gonadal regression in Syrian hamsters exposed to short day lengths. Am J Physiol Regul Integr Comp Physiol (2002) 0.87
PCOR, CER, and CBPR: alphabet soup or complementary fields of health research? Clin Transl Sci (2013) 0.85
Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J Virol (2010) 0.85
Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay. J Urol (2011) 0.85
Assessment of the amplitude of oscillations associated with high-frequency components of physiological tremor: impact of loading and signal differentiation. Exp Brain Res (2005) 0.84
Differential multimerization of Moloney murine leukemia virus integrase purified under nondenaturing conditions. Virology (2003) 0.83
Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+ lymphocytes. Virology (2009) 0.83
Pattern of nonspecific (or global) DNA methylation in oral carcinogenesis. Head Neck (2005) 0.83
Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines. PLoS One (2012) 0.83
Translating guidelines to practice: findings from a multidisciplinary preventive cardiology programme in the west of Ireland. Eur J Prev Cardiol (2013) 0.82
International Charter on Cardiovascular Prevention and Rehabilitation: a call for action. J Cardiopulm Rehabil Prev (2013) 0.82
Porins increase copper susceptibility of Mycobacterium tuberculosis. J Bacteriol (2013) 0.82
4-Dihydromethyltrisporate dehydrogenase, an enzyme of the sex hormone pathway in Mucor mucedo, is constitutively transcribed but its activity is differently regulated in (+) and (-) mating types. Fungal Genet Biol (2005) 0.82
Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs. Curr HIV Res (2011) 0.82